International Society of Nephrology

Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones

Retrieved on: 
Tuesday, January 23, 2024

LOS ALTOS, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today issued a letter to shareholders.

Key Points: 
  • As I sit down to write this letter, I am filled with a profound sense of gratitude and excitement, energized for the year ahead.
  • In this letter, I am pleased to recap for you another year of great accomplishments.
  • We’ve made significant advancements in our clinical programs which will propel us to new heights in 2024.
  • I would like to express my deep appreciation to the physician investigators, study participants, and especially to our dedicated Unicycive employees.

Invizius Announces Appointment of World-Renowned Nephrologist Professor Bernard Canaud to its Clinical Advisory Board

Retrieved on: 
Tuesday, October 24, 2023

GLASGOW, Scotland, Oct. 24, 2023 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board.

Key Points: 
  • GLASGOW, Scotland, Oct. 24, 2023 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board.
  • Professor Canaud is a leading authority on kidney disease and dialysis.
  • Richard Boyd, Chief Executive Officer of Invizius, said: "We are delighted and honored to have Professor Canaud join Invizius at an important time of growth and development for the company.
  • Professor Bernard Canaud, commented: "Invizius' unique product H-Guard has the potential to reduce the therapeutic burden and save patients' lives by addressing the inappropriate activation of the complement system.

Invizius Announces Appointment of World-Renowned Nephrologist Professor Bernard Canaud to its Clinical Advisory Board

Retrieved on: 
Tuesday, October 24, 2023

GLASGOW, Scotland, Oct. 24, 2023 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board.

Key Points: 
  • GLASGOW, Scotland, Oct. 24, 2023 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board.
  • Professor Canaud is a leading authority on kidney disease and dialysis.
  • Richard Boyd, Chief Executive Officer of Invizius, said: "We are delighted and honored to have Professor Canaud join Invizius at an important time of growth and development for the company.
  • Professor Bernard Canaud, commented: "Invizius' unique product H-Guard has the potential to reduce the therapeutic burden and save patients' lives by addressing the inappropriate activation of the complement system.

Genexine’s Long-acting Anemia Treatment GX-E4 Phase 3 Clinical Trial Interim Result Is Presented at WCN2023, Confirmed Non-inferiority Compared to Mircera

Retrieved on: 
Tuesday, April 11, 2023

Its non-inferiority results compared to Mircera (Methoxy Polyethylene Glycol-epoetin beta) were presented at the World Congress of Nephrology (WCN2023).

Key Points: 
  • Its non-inferiority results compared to Mircera (Methoxy Polyethylene Glycol-epoetin beta) were presented at the World Congress of Nephrology (WCN2023).
  • Kidneys are responsible for 90% of the EPO produced in our bodies.
  • CKD-induced anemia is caused by the failure to produce EPO (erythropoietin) due to long-term decreased kidney function.
  • It is aimed to confirm non-inferiority by administering and comparing with Roche's Mircera, a third-generation long-acting anemia treatment.

The National Kidney Foundation Honors Utah Nephrologist, Researcher with Prestigious Award

Retrieved on: 
Thursday, April 6, 2023

The award will be presented at the NKF Spring Clinical Meetings in Austin, TX this month.

Key Points: 
  • The award will be presented at the NKF Spring Clinical Meetings in Austin, TX this month.
  • I am very surprised, humbled and appreciative of this tremendous honor to receive the prestigious Hume award.
  • His research has focused on chronic kidney disease, hemodialysis, vascular access and hypertension.
  • It is the only conference of its kind that focuses on translating science into practice for the entire healthcare team.

INTERNATIONAL SOCIETY OF NEPHROLOGY LAUNCHES GLOBAL KIDNEY HEALTH REPORT THAT SHEDS LIGHT ON CURRENT CAPACITY AROUND THE WORLD TO DELIVER KIDNEY CARE

Retrieved on: 
Thursday, March 30, 2023

BRUSSELS, March 30, 2023 /PRNewswire/ -- Today (March 30, 2023), at the Professor Donal O'Donoghue Global Kidney Policy Forum at the World Congress of Nephrology (WCN 2023) in Bangkok, Thailand, the International Society of Nephrology (ISN) presented the highlights from its third, 2023 edition of the ISN-Global Kidney Health Atlas (ISN-GKHA).

Key Points: 
  • BRUSSELS, March 30, 2023 /PRNewswire/ -- Today (March 30, 2023), at the Professor Donal O'Donoghue Global Kidney Policy Forum at the World Congress of Nephrology (WCN 2023) in Bangkok, Thailand, the International Society of Nephrology (ISN) presented the highlights from its third, 2023 edition of the ISN-Global Kidney Health Atlas (ISN-GKHA).
  • A multinational study surveying the burden of kidney disease, the 2023 ISN-GKHA shows that, from the approximately 850 million people affected by chronic kidney disease (CKD) worldwide, people of every age and race are affected, and people from disadvantaged populations are at higher risk.
  • The 2023 ISN-GKHA also reveals that the global burden of kidney failure remains significant, due to high treatment costs and extensive impacts on the health and well-being of people living with kidney disease.
  • Reach out to Professor David Johnson and Professor Aminu Bello (co-chairs of the ISN-GKHA) at [email protected] and [email protected] to arrange an interview.

INTERNATIONAL SOCIETY OF NEPHROLOGY LAUNCHES GLOBAL KIDNEY HEALTH REPORT THAT SHEDS LIGHT ON CURRENT CAPACITY AROUND THE WORLD TO DELIVER KIDNEY CARE

Retrieved on: 
Thursday, March 30, 2023

BRUSSELS, March 30, 2023 /PRNewswire/ -- Today (March 30, 2023), at the Professor Donal O'Donoghue Global Kidney Policy Forum at the World Congress of Nephrology (WCN 2023) in Bangkok, Thailand, the International Society of Nephrology (ISN) presented the highlights from its third, 2023 edition of the ISN-Global Kidney Health Atlas (ISN-GKHA).

Key Points: 
  • BRUSSELS, March 30, 2023 /PRNewswire/ -- Today (March 30, 2023), at the Professor Donal O'Donoghue Global Kidney Policy Forum at the World Congress of Nephrology (WCN 2023) in Bangkok, Thailand, the International Society of Nephrology (ISN) presented the highlights from its third, 2023 edition of the ISN-Global Kidney Health Atlas (ISN-GKHA).
  • A multinational study surveying the burden of kidney disease, the 2023 ISN-GKHA shows that, from the approximately 850 million people affected by chronic kidney disease (CKD) worldwide, people of every age and race are affected, and people from disadvantaged populations are at higher risk.
  • The 2023 ISN-GKHA also reveals that the global burden of kidney failure remains significant, due to high treatment costs and extensive impacts on the health and well-being of people living with kidney disease.
  • Reach out to Professor David Johnson and Professor Aminu Bello (co-chairs of the ISN-GKHA) at [email protected] and [email protected] to arrange an interview.

Global Hemodialysis and Peritoneal Dialysis Market Analysis/Forecast 2022-2028: Market Strategies by Key Players & Shift in Preference of Patients for Home Care Dialysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 31, 2022

The presence of competitive market players introducing advanced products and services with innovative strategies acts as a future trend of the hemodialysis and peritoneal dialysis market.

Key Points: 
  • The presence of competitive market players introducing advanced products and services with innovative strategies acts as a future trend of the hemodialysis and peritoneal dialysis market.
  • The global hemodialysis and peritoneal dialysis market is segmented on the basis of type, product, and end user.
  • Additionally, the Regents of the University of California report states that various health centers offer quality hemodialysis and peritoneal dialysis services.
  • Such aforementioned factors would highly support the growth of the hemodialysis and peritoneal dialysis market during the forecast period.

Terumo Blood and Cell Technologies collaborates with Eliaz Therapeutics in the development and commercialization of a novel therapeutic apheresis treatment for acute kidney injury (AKI)

Retrieved on: 
Wednesday, July 27, 2022

Terumo Blood and Cell Technologies specializes in a portfolio of technology, software and services for blood component collection, therapeutic apheresis and cellular technologies.

Key Points: 
  • Terumo Blood and Cell Technologies specializes in a portfolio of technology, software and services for blood component collection, therapeutic apheresis and cellular technologies.
  • Working with Terumo Blood and Cell Technologies could bring broad availability of this therapy to the global marketplace."
  • Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices.
  • Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.

ProKidney Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

Retrieved on: 
Wednesday, July 20, 2022

as Senior Vice President of Medical Affairs.

Key Points: 
  • as Senior Vice President of Medical Affairs.
  • Dr. Cooper, who will report to Chief Medical Officer Dr. Libbie McKenzie, joins ProKidney from AstraZeneca, where he was Vice President, U.S. Medical Affairs Renal Division.
  • He led medical teams on nephrology programs, including Lokelma, and contributed to cross functional teams advancing therapeutics utilized by CKD patients.
  • Dr. Libbie McKenzie, CMO of ProKidney, said: On behalf of our entire team, I am delighted to welcome Dr. Cooper to ProKidney.